“Bimekizumab Response Maintenance to 48 Weeks in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s396. doi:10.25251/skin.8.supp.396.